Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. / Raket, Lars Lau; Kühnel, Line; Schmidt, Ellen; Blennow, Kaj; Zetterberg, Henrik; Mattsson-Carlgren, Niklas.
I: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Bind 12, Nr. 1, e12099, 2020.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
AU - Raket, Lars Lau
AU - Kühnel, Line
AU - Schmidt, Ellen
AU - Blennow, Kaj
AU - Zetterberg, Henrik
AU - Mattsson-Carlgren, Niklas
PY - 2020
Y1 - 2020
N2 - Introduction: Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Methods: Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. Results: NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points). NfL held independent information about shorter-term (3- to 6-month) progression beyond patient age and clinical scores. However, no meaningful gain in power was found when adjusting a longitudinal analysis of cognitive scores for baseline NfL. Discussion: Plasma NfL is superior to t-tau in mild AD. The ability of NfL to detect changes before clinical manifestations makes it a promising biomarker of drug response in trials of disease-modifying drugs.
AB - Introduction: Several blood-based biomarkers are associated with neuronal injury, but their utility in interventional clinical trials is unclear. This study retrospectively evaluated the utility of plasma neurofilament light (NfL) and total tau (t-tau) in an 18-month trial in mild Alzheimer's disease (AD). Methods: Correlation and conditional independence analyses and Gaussian graphical models were used to investigate cross-sectional and longitudinal relations between NfL, t-tau, and clinical scales. Results: NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points). NfL held independent information about shorter-term (3- to 6-month) progression beyond patient age and clinical scores. However, no meaningful gain in power was found when adjusting a longitudinal analysis of cognitive scores for baseline NfL. Discussion: Plasma NfL is superior to t-tau in mild AD. The ability of NfL to detect changes before clinical manifestations makes it a promising biomarker of drug response in trials of disease-modifying drugs.
KW - Alzheimer's disease
KW - biomarkers
KW - blood biomarkers
KW - clinical trials
KW - dementia
KW - fluid biomarkers
KW - neurofilament light
KW - NfL
KW - plasma biomarkers
KW - t-tau
KW - total tau
UR - http://www.scopus.com/inward/record.url?scp=85100509312&partnerID=8YFLogxK
U2 - 10.1002/dad2.12099
DO - 10.1002/dad2.12099
M3 - Journal article
C2 - 32995466
AN - SCOPUS:85100509312
VL - 12
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
SN - 2352-8729
IS - 1
M1 - e12099
ER -
ID: 257366693